Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 05, 2022 16:05 ET
|
Longboard Pharmaceuticals, Inc.
Phase 1 data for LP352, a potential treatment for seizures associated with a broad range of severe epilepsies, presented at the American Academy of Neurology (AAN) Annual MeetingInitiated Phase 1b/2a...
Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results
March 03, 2022 16:05 ET
|
Longboard Pharmaceuticals, Inc.
Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs)LP352 demonstrated statistically significant reduction of epileptiform...
Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 04, 2021 16:05 ET
|
Longboard Pharmaceuticals, Inc.
Successfully completed multiple ascending dose (MAD) portion of a Phase 1 clinical trial for LP352, a potential treatment for seizures associated with a broad range of severe epilepsiesInitiating a...
Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 10, 2021 16:05 ET
|
Longboard Pharmaceuticals, Inc.
Commenced multiple ascending dose (MAD) portion of the Phase 1 study for LP352, a potential treatment for severe epileptic indications; topline results expected in the second half of 2021 ...